3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
218
Recurrence
24
Neoplasms, Plasma Cell
15
Immunoglobulin Light-chain Amyloidosis
13
Neoplasms
12
Lymphoma, Non-Hodgkin
6
Smoldering Multiple Myeloma
5
Leukemia, Myeloid, Acute
4
Plasmacytoma
3
Paraproteinemias
3
Leukemia, Plasma Cell
3
Hematologic Neoplasms
3
Hematologic Diseases
3
Amyloidosis
3
Neoplasm, Residual
2
Hodgkin Disease
2
Disease
2
Corneal Diseases
2
Blood Protein Disorders
2
Acute Kidney Injury
2
Triple Negative Breast Neoplasms
1
Renal Insufficiency
1
Proteostasis Deficiencies
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Personal Satisfaction
1
Patient Satisfaction
1
Patient Preference
1
Myelodysplastic Syndromes
1
Lymphoma, T-Cell, Peripheral
1
Interventions
daratumumab
1
Patient Transfer
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Patient Satisfaction
×
daratumumab
×
Plasma cell
×
Clear all
NCT05284591
2024-10-01
MYLENE
iOMEDICO AG
Completed
96 enrolled